SG11201810704WA - Sulfonamide compound or salt thereof - Google Patents
Sulfonamide compound or salt thereofInfo
- Publication number
- SG11201810704WA SG11201810704WA SG11201810704WA SG11201810704WA SG11201810704WA SG 11201810704W A SG11201810704W A SG 11201810704WA SG 11201810704W A SG11201810704W A SG 11201810704WA SG 11201810704W A SG11201810704W A SG 11201810704WA SG 11201810704W A SG11201810704W A SG 11201810704WA
- Authority
- SG
- Singapore
- Prior art keywords
- salt
- sulfonamide compound
- hydrogen atom
- optionally substituted
- hydrocarbon group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Abstract
Sulfonamide compound or salt thereof The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical 5 composition containing the same as an active ingredient. A compound represented by Formula (I) [wherein, X 1 represents an oxygen atom or the like; X 2 represents an oxygen atom; X 3 represents -NH-; X 4 represents a hydrogen atom or the like; R 1 represents -C (R 11 ) (R 12 )- or the like; R 11 and R 12 are the same or different and each represents a hydrogen atom or the like; R 2 represents an optionally substituted C 6 -C14 10 aromatic hydrocarbon group or the like; R 3 represents an optionally substituted C 6 -C14 aromatic hydrocarbon group or the like; R 4 represents a hydrogen atom or the like] or a salt thereof. [No suitable figure] 15
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016109609 | 2016-05-31 | ||
PCT/JP2017/020166 WO2017209155A1 (en) | 2016-05-31 | 2017-05-30 | Sulfonamide compound or salt thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201810704WA true SG11201810704WA (en) | 2018-12-28 |
Family
ID=60478546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810704WA SG11201810704WA (en) | 2016-05-31 | 2017-05-30 | Sulfonamide compound or salt thereof |
Country Status (18)
Country | Link |
---|---|
US (1) | US11634395B2 (en) |
EP (1) | EP3466934B1 (en) |
JP (1) | JP6532607B2 (en) |
KR (2) | KR102543559B1 (en) |
CN (1) | CN109563057B (en) |
AU (1) | AU2017275209C1 (en) |
BR (1) | BR112018074646A2 (en) |
CA (1) | CA3025887C (en) |
DK (1) | DK3466934T3 (en) |
FI (1) | FI3466934T3 (en) |
MA (1) | MA45185A (en) |
MX (1) | MX2018014762A (en) |
MY (1) | MY194676A (en) |
PH (1) | PH12018502513A1 (en) |
RU (1) | RU2732572C2 (en) |
SG (1) | SG11201810704WA (en) |
TW (1) | TWI746562B (en) |
WO (1) | WO2017209155A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3466934T3 (en) | 2016-05-31 | 2024-04-15 | Taiho Pharmaceutical Co Ltd | SULFONAMIDE COMPOUNDS OR SALT THEREOF AS RIBONUCLEOTIDE REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER |
SG11202004877UA (en) * | 2017-11-29 | 2020-06-29 | Taiho Pharmaceutical Co Ltd | Sulfonamide compounds and use thereof |
US20200405697A1 (en) * | 2017-11-29 | 2020-12-31 | Taiho Pharmaceutical Co., Ltd. | Antitumor Agent |
US20220002284A1 (en) | 2018-11-28 | 2022-01-06 | Basf Se | Pesticidal compounds |
CN109608352A (en) * | 2018-12-28 | 2019-04-12 | 凯瑞斯德生化(苏州)有限公司 | A kind of preparation method of 2,6- dimethyl-l-tyrosine |
CN110066308B (en) * | 2019-04-26 | 2022-05-27 | 上海药明康德新药开发有限公司 | Synthetic method of On-DNA sulfonamide compound for constructing DNA coding compound library |
TWI781405B (en) * | 2019-05-29 | 2022-10-21 | 日商大鵬藥品工業股份有限公司 | Cancer Combination Therapy Using Sulfamides and Immunomodulators |
BR112022021631A2 (en) | 2020-04-28 | 2022-12-06 | Basf Se | COMPOUNDS, COMPOSITION, METHODS TO COMBAT OR CONTROL INVERTEBRATE PEST, TO PROTECT GROWING PLANTS AND TO TREAT OR PROTECT AN ANIMAL, SEED AND USE OF A COMPOUND |
WO2022187200A1 (en) * | 2021-03-02 | 2022-09-09 | Boundless Bio, Inc. | Ribonucleotide reductase (rnr) inhibitors and uses thereof |
WO2023043938A1 (en) * | 2021-09-17 | 2023-03-23 | Boundless Bio, Inc. | Sulfamide ribonucleotide reductase (rnr) inhibitors and uses thereof |
TW202328121A (en) * | 2021-09-17 | 2023-07-16 | 美商無界生物公司 | Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof |
WO2024059563A1 (en) * | 2022-09-13 | 2024-03-21 | Boundless Bio, Inc. | Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof |
CN117024616A (en) * | 2023-07-10 | 2023-11-10 | 张琦 | Preparation and application of brown algae polysaccharide derivative nano micelle |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
US6689762B1 (en) * | 1998-02-09 | 2004-02-10 | Enzon Pharmaceuticals, Inc. | Composition and methods for treatment of HIV infection |
WO2000029375A1 (en) * | 1998-11-17 | 2000-05-25 | Kyowa Hakko Kogyo Co., Ltd. | Bisaryl compounds and cancer remedies containing the same |
AU6894400A (en) * | 1999-08-06 | 2001-03-05 | Enzon Pharmaceuticals Inc. | Composition and methods for treatment of HIV infection |
CA2407799A1 (en) | 2000-05-02 | 2001-11-08 | Sugen, Inc. | (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors |
SK2502003A3 (en) | 2000-08-31 | 2004-03-02 | Reddys Lab Ltd Dr | Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine |
FI2206517T3 (en) | 2002-07-03 | 2023-10-19 | Ono Pharmaceutical Co | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
AU2003257170B2 (en) * | 2002-08-09 | 2008-12-11 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
EP1798226A4 (en) | 2004-08-04 | 2009-06-17 | Taisho Pharmaceutical Co Ltd | Triazole derivative |
MY142304A (en) * | 2005-01-31 | 2010-11-15 | Taiho Pharmaceutical Co Ltd | Novel pyrimidine nucleoside compound or salt thereof |
TW200736234A (en) * | 2006-01-17 | 2007-10-01 | Astrazeneca Ab | Chemical compounds |
EP1988083B1 (en) | 2006-02-03 | 2014-04-02 | Taisho Pharmaceutical Co., Ltd. | Triazole derivative |
AU2008287542C1 (en) * | 2007-06-01 | 2015-01-22 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
US20110177999A1 (en) * | 2007-08-09 | 2011-07-21 | Vertex Pharmaceuticals Incorporated | Therapeutic Combinations Useful in Treating CFTR Related Diseases |
NZ591999A (en) | 2008-11-11 | 2013-06-28 | Novartis Ag | Salts of fingolimod fty720 |
EP2509960A1 (en) | 2009-12-11 | 2012-10-17 | Exelixis, Inc. | Tgr5 agonists |
WO2011121453A2 (en) | 2010-03-30 | 2011-10-06 | Clavis Pharma Asa | Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate |
TWI623316B (en) | 2015-12-22 | 2018-05-11 | Taiho Pharmaceutical Co Ltd | Antitumor effect enhancer derived from pyrrolopyrimidine compound |
KR20240014585A (en) | 2016-03-04 | 2024-02-01 | 다이호야쿠힌고교 가부시키가이샤 | Preparation and composition for treatment of malignant tumors |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
US10889555B2 (en) | 2016-05-31 | 2021-01-12 | Taiho Pharmaceutical Co., Ltd. | Sulfonamide compound or salt thereof |
DK3466934T3 (en) | 2016-05-31 | 2024-04-15 | Taiho Pharmaceutical Co Ltd | SULFONAMIDE COMPOUNDS OR SALT THEREOF AS RIBONUCLEOTIDE REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER |
US20200405697A1 (en) | 2017-11-29 | 2020-12-31 | Taiho Pharmaceutical Co., Ltd. | Antitumor Agent |
SG11202004877UA (en) | 2017-11-29 | 2020-06-29 | Taiho Pharmaceutical Co Ltd | Sulfonamide compounds and use thereof |
-
2017
- 2017-05-30 DK DK17806708.8T patent/DK3466934T3/en active
- 2017-05-30 KR KR1020217023222A patent/KR102543559B1/en active IP Right Grant
- 2017-05-30 SG SG11201810704WA patent/SG11201810704WA/en unknown
- 2017-05-30 MX MX2018014762A patent/MX2018014762A/en unknown
- 2017-05-30 JP JP2018520941A patent/JP6532607B2/en active Active
- 2017-05-30 FI FIEP17806708.8T patent/FI3466934T3/en active
- 2017-05-30 AU AU2017275209A patent/AU2017275209C1/en active Active
- 2017-05-30 EP EP17806708.8A patent/EP3466934B1/en active Active
- 2017-05-30 CN CN201780045742.8A patent/CN109563057B/en active Active
- 2017-05-30 RU RU2018145761A patent/RU2732572C2/en active
- 2017-05-30 WO PCT/JP2017/020166 patent/WO2017209155A1/en unknown
- 2017-05-30 MA MA045185A patent/MA45185A/en unknown
- 2017-05-30 CA CA3025887A patent/CA3025887C/en active Active
- 2017-05-30 MY MYPI2018002215A patent/MY194676A/en unknown
- 2017-05-30 KR KR1020187038233A patent/KR102311737B1/en active IP Right Grant
- 2017-05-30 BR BR112018074646-0A patent/BR112018074646A2/en active Search and Examination
- 2017-05-31 TW TW106117994A patent/TWI746562B/en active
-
2018
- 2018-11-28 PH PH12018502513A patent/PH12018502513A1/en unknown
-
2020
- 2020-08-24 US US17/000,807 patent/US11634395B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA3025887C (en) | 2022-06-28 |
MA45185A (en) | 2019-04-10 |
KR20190015731A (en) | 2019-02-14 |
JPWO2017209155A1 (en) | 2019-04-18 |
DK3466934T3 (en) | 2024-04-15 |
KR102311737B1 (en) | 2021-10-12 |
FI3466934T3 (en) | 2024-04-23 |
EP3466934B1 (en) | 2024-03-27 |
TWI746562B (en) | 2021-11-21 |
CN109563057A (en) | 2019-04-02 |
RU2018145761A3 (en) | 2020-07-10 |
PH12018502513A1 (en) | 2019-10-21 |
MX2018014762A (en) | 2019-04-25 |
BR112018074646A2 (en) | 2019-03-06 |
WO2017209155A1 (en) | 2017-12-07 |
CN109563057B (en) | 2022-06-24 |
CA3025887A1 (en) | 2017-12-07 |
US11634395B2 (en) | 2023-04-25 |
EP3466934A4 (en) | 2019-12-11 |
RU2018145761A (en) | 2020-07-10 |
RU2732572C2 (en) | 2020-09-21 |
US20200399235A1 (en) | 2020-12-24 |
EP3466934A1 (en) | 2019-04-10 |
AU2017275209C1 (en) | 2020-01-23 |
TW201800395A (en) | 2018-01-01 |
MY194676A (en) | 2022-12-13 |
JP6532607B2 (en) | 2019-06-19 |
AU2017275209B2 (en) | 2019-10-03 |
KR102543559B1 (en) | 2023-06-13 |
AU2017275209A1 (en) | 2019-01-17 |
KR20210093395A (en) | 2021-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201810704WA (en) | Sulfonamide compound or salt thereof | |
WO2017019804A3 (en) | Compounds and methods for kinase modulation, and indications therefor | |
AU2018312326A2 (en) | Heterocyclic compound and use thereof | |
NZ723312A (en) | 1,3-benzodioxole derivative | |
EP4071149A3 (en) | Heterocyclic compounds and uses thereof | |
SG11201804121RA (en) | Novel biphenyl compound or salt thereof | |
MX2012007060A (en) | Nitrogen-containing heterocyclic compound and agricultural/horticultural germicide. | |
MY196809A (en) | (),()-unsaturated amide compound | |
GEP201606555B (en) | Compounds and compositions for modulating egfr activity | |
PH12019500394A1 (en) | Bicyclic nitrogenated heterocyclic compound | |
MX2019014104A (en) | Novel biphenyl compound or salt thereof. | |
WO2009082152A3 (en) | Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient | |
MX2022014864A (en) | Bisamide sarcomere activating compounds and uses thereof. | |
MX2020009530A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors. | |
EA201201263A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING DAGIGATRAN ETEXYLATE | |
MX2022002976A (en) | Jak1 selective inhibitors. | |
MX2021004474A (en) | Compounds containing deuterium. | |
NZ608846A (en) | Aryloxyurea compound and pest control agent | |
MX2021014680A (en) | Benzotriazole derivative. | |
UA112556C2 (en) | INSECTICID DERIVATIVES OF 2-METOXYBENZAMIDES | |
NZ627473A (en) | Aryloxyacetamide compound and pesticide | |
NZ738953A (en) | Production method for nitrogen-containing heterocyclic compound, and intermediate of said nitrogen-containing heterocyclic compound | |
MX2019004293A (en) | 4-amino substituted phenylamidine derivatives and their use to protect crops by fighting undesired phytopathogenic micoorganisms. | |
MX2022008665A (en) | Novel pyrazole derivative. | |
WO2014013951A8 (en) | Pyridine compound and agricultural fungicide |